Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
By: Faith Ashmore Benzinga Staff Writer As of 2023,, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in dementia
By: Faith Ashmore Benzinga Staff Writer Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact
On this day let’s talk about the power of education and how it can bring hope and understanding to patients, caregivers, and families affected by this condition.
IGC will aim for FDA fast-track designation after a Phase II trial investigating IGC-AD1 with AD patients concludes in Q1 2024.
Discover cutting-edge dementia science at AAIC Amsterdam. Breakthroughs and connections thrive as leading experts unite at the world’s largest conference on Alzheimer’s research.
On May 14, Prof Govindaraju received the Government of India-instituted National Technology Award for outstanding contribution in commercialising innovative indigenous technologies from the Minister of State for Science and Technology and Earth Sciences, Dr Jitendra Singh.
Hamsa Biopharma, which will take the drug ” Christened TGR63” to trials through its parent company in the US, IGC Pharma, hopes it can eventually be made available in the market.
Researchers in India say they have discovered a promising drug target that may slow or even halt the progression of Alzheimer’s.
Subscribe to get our latest content by email.
